Filing Details

Accession Number:
0001628280-24-009014
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-05 17:13:45
Reporting Period:
2024-03-04
Accepted Time:
2024-03-05 17:13:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1490978 Schrodinger Inc. SDGR Pharmaceutical Preparations (2834) 954284541
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1938826 Craig Geoffrey Porges 1540 Broadway, 24Th Floor
New York NY 10036
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-04 9,000 $0.00 9,000 No 4 A Direct
Common Stock Disposition 2024-03-04 3,315 $26.35 5,685 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2024-03-04 90,000 $0.00 90,000 $25.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
90,000 2034-03-04 No 4 A Direct
Footnotes
  1. Represents the portion of the performance-based restricted stock units ("PRSUs") that were awarded to the reporting person on August 18, 2022 in connection with the commencement of his employment that vested on March 4, 2024 following certification by the compensation committee of the issuer's board of directors of the level of achievement of certain performance metrics for the PRSUs.
  2. This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on August 16, 2022 and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of the PRSUs on March 4, 2024. The sale does not represent a discretionary trade by the reporting person.
  3. The option was granted on March 4, 2024. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 4, 2025 and the remainder are scheduled to vest in equal monthly installments through March 4, 2028.